Trial Profile

A Non-randomized, Open-label, Multi-center, Phase I/II Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Copanlisib in Pediatric Patients With Relapsed/Refractory Solid Tumors or Lymphoma

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 06 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Copanlisib (Primary)
Indications Ewing's sarcoma; Lymphoma; Neuroblastoma; Osteosarcoma; Rhabdomyosarcoma; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors Bayer

Most Recent Events

28 Feb 2023 Status changed from recruiting to discontinued.
28 Oct 2022 Results(n=23) assessing safety, efficacy, and pharmacokinetics (PK) of copanlisib in pediatric pts with relapsed/refractory solid tumors presented at the 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics
16 Jun 2020 Planned number of patients changed from 130 to 142.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com